Clinical Research

Cardurion Pharmaceuticals Inc.

Address
78 Blanchard Road Suite 200

Sponsor Overview

assignment
4
sponsored trials
science
2
molecules
location_city
95
research centres
public
13
countries
person_search
98
investigators

Specializations

Heart Failure and Cardiac Function

Cardurion Pharmaceuticals Inc. focuses on heart failure, with research spanning heart failure with reduced ejection fraction and heart failure with preserved ejection fraction. Its clinical work is centered on cardiac biomarker-driven evaluation and treatment of chronic symptomatic disease.

  • Heart failure with reduced ejection fraction
  • Heart failure with preserved ejection fraction
  • Chronic heart failure
  • NT-proBNP-related cardiac assessment

The sponsor’s research interest in this area reflects a concentration on improving outcomes in patients with impaired cardiac performance and persistent circulatory stress.

Arrhythmia and Inherited Rhythm Disorders

The company also investigates catecholaminergic polymorphic ventricular tachycardia, a rare inherited ventricular arrhythmia associated with stress-triggered rhythm instability. This area of research addresses cardiac electrical disorders with a distinct genetic and electrophysiologic basis.

  • Catecholaminergic polymorphic ventricular tachycardia
  • Inherited ventricular arrhythmia
  • Cardiac rhythm stability
  • Electrophysiologic disorders

Research in this domain highlights interest in conditions where abnormal adrenergic responses contribute to potentially serious rhythm disturbances.

Cardiovascular Biomarkers and Disease Monitoring

Cardurion’s clinical portfolio includes studies using NT-proBNP as a marker of cardiac stress and disease burden in chronic heart failure. This indicates a therapeutic interest in biomarker-informed assessment of cardiovascular disease activity.

  • NT-proBNP
  • Cardiac stress biomarkers
  • Heart failure monitoring
  • Disease burden assessment

The sponsor’s work in this field is tied to measuring clinically relevant changes in cardiac status across heart failure populations.

Cardiovascular Therapeutics

The funded trials reflect a broader commitment to cardiovascular therapeutics, with attention to conditions that involve both mechanical pump dysfunction and electrical instability of the heart. The research landscape is concentrated in adult cardiology and rare cardiac disease.

  • Adult cardiology
  • Rare cardiac disease
  • Cardiac dysfunction
  • Ventricular tachyarrhythmia

These areas show a therapeutic focus on clinically significant disorders of cardiac performance and rhythm in both common and uncommon patient groups.

Sponsored Trials

Trial Name Country Status
A PHASE 2A, INVESTIGATOR AND SUBJECT BLINDED, SPONSOR UNBLINDED, PLACEBO-CONTROLLED, CLINICAL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF CRD-4730 IN PARTICIPANTS WITH CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIAFrance FranceItaly ItalyNot Recruiting
Evaluation of CRD-4730 Safety and Tolerability in Catecholaminergic Polymorphic Ventricular Tachycardia: A Phase 2 Double-Blind, Placebo-Controlled Crossover StudyFrance FranceItaly ItalySpain SpainThe Netherlands The NetherlandsRecruiting
Evaluation of Tovinontrine on NT-proBNP Levels in Adults with Chronic Heart Failure with Preserved Ejection Fraction: A Phase 2 Randomized, Double-Blind, Placebo-Controlled StudyBelgium BelgiumBulgaria BulgariaCzechia CzechiaGermany GermanyHungary HungaryItaly ItalyPoland PolandSpain SpainThe Netherlands The NetherlandsNot Recruiting
Phase 2 Randomized Double-Blind Placebo-Controlled Study of Tovinontrine in Adults with Heart Failure with Reduced Ejection FractionBelgium BelgiumBulgaria BulgariaCzechia CzechiaGermany GermanyHungary HungaryItaly ItalyLatvia LatviaLithuania LithuaniaPoland PolandSlovakia SlovakiaSpain SpainThe Netherlands The NetherlandsNot Recruiting

Data & Insights

science
Molecule Portfolio
Compounds under investigation
2
Exclusive Molecules
out of 2 total (100% not shared with other sponsors)

This sponsor works with 2 molecules, of which 2 are not being studied by other sponsors.

hub
Site Partnerships
Collaboration with research centres
53%
Return partnership rate
50 of 95 sites collaborated multiple times

This sponsor has worked with 95 sites across their trial portfolio.

Therapeutic Focus

  • 1.
    Cardiovascular Diseases4 trials
    359 other sponsors
  • 2.
    Congenital, Hereditary, and Neonatal Diseases and Abnormalities1 trial
    165 other sponsors

Partnered Research Centres

95 centres
location_city
assignment32
1 Wojskowy Szpital Kliniczny Z Poliklinika samodzielny publiczny zakład opieki zdrowotnej W Lublinie
Address
Ul. Aleje Raclawickie 23, 20-049 Lublin
Learn morearrow_forward
location_city
assignment60
4 Wojskowy SzpitaKliniczny Z Polikliniką Samodzielny Publiczny ZakładOpieki ZdrowotneWe Wrocławiu
Address
Ul. Rudolfa Weigla 5, 53-114 Wroclaw
Learn morearrow_forward
location_city
assignment38
Admiraal De Ruyter Ziekenhuis B.V.
Address
'S-Gravenpolderseweg 114, 4462 RA Goes
Learn morearrow_forward
location_city
assignment163
Algemeen Ziekenhuis Groeninge
Address
President Kennedylaan 4, 8500 Kortrijk
Learn morearrow_forward
location_city
assignment38
Alian s.r.o.
Address
Sv. Jakuba 33, 085 01 Bardejov
Learn morearrow_forward
location_city
assignment680
Amsterdam UMC
Address
De Boelelaan 1117, 1081 HV Amsterdam
Learn morearrow_forward
Page 1 of 16

Want to get in touch with this sponsor?

Send a question and we'll pass it on to Cardurion Pharmaceuticals Inc..

Need a custom report on this sponsor?

Competitive positioning, market entry, partnership opportunities — tell us the question.

Is something out of date?

Tell us what needs correcting and we'll update this profile.